Literature DB >> 15350157

Safety related drug-labelling changes: findings from two data mining algorithms.

Manfred Hauben1, Lester Reich.   

Abstract

INTRODUCTION: With increasing volumes of postmarketing safety surveillance data, data mining algorithms (DMAs) have been developed to search large spontaneous reporting system (SRS) databases for disproportional statistical dependencies between drugs and events. A crucial question is the proper deployment of such techniques within the universe of methods historically used for signal detection. One question of interest is comparative performance of algorithms based on simple forms of disproportionality analysis versus those incorporating Bayesian modelling. A potential benefit of Bayesian methods is a reduced volume of signals, including false-positive signals.
OBJECTIVE: To compare performance of two well described DMAs (proportional reporting ratios [PRRs] and an empirical Bayesian algorithm known as multi-item gamma Poisson shrinker [MGPS]) using commonly recommended thresholds on a diverse data set of adverse events that triggered drug labelling changes.
METHODS: PRRs and MGPS were retrospectively applied to a diverse sample of drug-event combinations (DECs) identified on a government Internet site for a 7-month period. Metrics for this comparative analysis included the number and proportion of these DECs that generated signals of disproportionate reporting with PRRs, MGPS, both or neither method, differential timing of signal generation between the two methods, and clinical nature of events that generated signals with only one, both or neither method.
RESULTS: There were 136 relevant DECs that triggered safety-related labelling changes for 39 drugs during a 7-month period. PRRs generated a signal of disproportionate reporting with almost twice as many DECs as MGPS (77 vs 40). No DECs were flagged by MGPS only. PRRs highlighted DECs in advance of MGPS (1-15 years) and a label change (1-30 years). For 59 DECs, there was no signal with either DMA. DECs generating signals of disproportionate reporting with only PRRs were both medically serious and non-serious. DISCUSSION/
CONCLUSION: In most instances in which a DEC generated a signal of disproportionate reporting with both DMAs (almost twice as many with PRRs), the signal was generated using PRRs in advance of MGPS. No medically important events were signalled only by MGPS. It is likely that the incremental utility of DMAs are highly situation-dependent. It is clear, however, that the volume of signals generated by itself is an inadequate criterion for comparison and that clinical nature of signalled events and differential timing of signals needs to be considered. Accepting commonly recommended threshold criteria for DMAs examined in this study as universal benchmarks for signal detection is not justified.

Entities:  

Mesh:

Year:  2004        PMID: 15350157     DOI: 10.2165/00002018-200427100-00004

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  11 in total

1.  Simpson's paradox: an example from hospital epidemiology.

Authors:  R Reintjes; A de Boer; W van Pelt; J Mintjes-de Groot
Journal:  Epidemiology       Date:  2000-01       Impact factor: 4.822

2.  A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database.

Authors:  M Lindquist; M Ståhl; A Bate; I R Edwards; R H Meyboom
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

3.  Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.

Authors:  S J Evans; P C Waller; S Davis
Journal:  Pharmacoepidemiol Drug Saf       Date:  2001 Oct-Nov       Impact factor: 2.890

4.  A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions.

Authors:  Eugène P van Puijenbroek; Andrew Bate; Hubert G M Leufkens; Marie Lindquist; Roland Orre; Antoine C G Egberts
Journal:  Pharmacoepidemiol Drug Saf       Date:  2002 Jan-Feb       Impact factor: 2.890

5.  On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios.

Authors:  Peter G M van der Heijden; Eugène P van Puijenbroek; Stef van Buuren; Jacques W van der Hofstede
Journal:  Stat Med       Date:  2002-07-30       Impact factor: 2.373

6.  Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.

Authors:  Ana Szarfman; Stella G Machado; Robert T O'Neill
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

7.  Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions.

Authors:  Eugène van Puijenbroek; Willem Diemont; Kees van Grootheest
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 8.  A brief primer on automated signal detection.

Authors:  Manfred Hauben
Journal:  Ann Pharmacother       Date:  2003 Jul-Aug       Impact factor: 3.154

9.  Practical pharmacovigilance analysis strategies.

Authors:  A Lawrence Gould
Journal:  Pharmacoepidemiol Drug Saf       Date:  2003 Oct-Nov       Impact factor: 2.890

10.  A Bayesian neural network method for adverse drug reaction signal generation.

Authors:  A Bate; M Lindquist; I R Edwards; S Olsson; R Orre; A Lansner; R M De Freitas
Journal:  Eur J Clin Pharmacol       Date:  1998-06       Impact factor: 2.953

View more
  16 in total

1.  Data mining in pharmacovigilance: the need for a balanced perspective.

Authors:  Manfred Hauben; Vaishali Patadia; Charles Gerrits; Louisa Walsh; Lester Reich
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 2.  Perspectives on the use of data mining in pharmaco-vigilance.

Authors:  June Almenoff; Joseph M Tonning; A Lawrence Gould; Ana Szarfman; Manfred Hauben; Rita Ouellet-Hellstrom; Robert Ball; Ken Hornbuckle; Louisa Walsh; Chuen Yee; Susan T Sacks; Nancy Yuen; Vaishali Patadia; Michael Blum; Mike Johnston; Charles Gerrits; Harry Seifert; Karol Lacroix
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Reply: The evaluation of data mining methods for the simultaneous and systematic detection of safety signals in large databases: lessons to be learned.

Authors:  Jonathan G Levine; Joseph M Tonning; Ana Szarfman
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

4.  Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.

Authors:  June S Almenoff; Karol K LaCroix; Nancy A Yuen; David Fram; William DuMouchel
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 5.  Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions.

Authors:  Manfred Hauben; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

6.  Data mining in pharmacovigilance--detecting the unexpected: the role of index of suspicion of the reporter.

Authors:  Anders Sundström; Pär Hallberg
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

7.  Prospective data mining of six products in the US FDA Adverse Event Reporting System: disposition of events identified and impact on product safety profiles.

Authors:  Steven Bailey; Ajay Singh; Robert Azadian; Peter Huber; Michael Blum
Journal:  Drug Saf       Date:  2010-02-01       Impact factor: 5.606

8.  Impact of stratification on adverse drug reaction surveillance.

Authors:  Johan Hopstadius; G Niklas Norén; Andrew Bate; I Ralph Edwards
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

9.  Stratification for spontaneous report databases.

Authors:  Stephen J W Evans
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

10.  A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.

Authors:  Keith B Hoffman; Mo Dimbil; Nicholas P Tatonetti; Robert F Kyle
Journal:  Drug Saf       Date:  2016-06       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.